Second Sight Medical (EYES) Receives News Impact Score of 0.35

News stories about Second Sight Medical (NASDAQ:EYES) have trended positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Second Sight Medical earned a daily sentiment score of 0.35 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 47.0605621880335 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of equities research analysts have recently issued reports on EYES shares. Zacks Investment Research raised shares of Second Sight Medical from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. HC Wainwright set a $5.00 price objective on shares of Second Sight Medical and gave the company a “buy” rating in a research note on Monday, February 5th.

How to Become a New Pot Stock Millionaire

NASDAQ:EYES traded down $0.03 during midday trading on Thursday, reaching $1.67. 36,996 shares of the stock traded hands, compared to its average volume of 572,821. Second Sight Medical has a 12 month low of $0.90 and a 12 month high of $2.58. The firm has a market capitalization of $104.18, a P/E ratio of -2.85 and a beta of 3.04.

Second Sight Medical (NASDAQ:EYES) last posted its quarterly earnings results on Wednesday, March 7th. The medical device company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. Second Sight Medical had a negative net margin of 358.06% and a negative return on equity of 197.61%. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $1.98 million. During the same period in the prior year, the business posted ($0.24) EPS. The firm’s revenue was up 333.6% compared to the same quarter last year. research analysts predict that Second Sight Medical will post -0.58 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at

Second Sight Medical Company Profile

Second Sight Medical Products, Inc develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, Canada, and Singapore. The company's product is the Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Insider Buying and Selling by Quarter for Second Sight Medical (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical and related companies with's FREE daily email newsletter.

Leave a Reply